Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Blacksand Technology was a U.S.-based advanced materials company focused on low-cost titanium and specialty alloy powders and sintered components for additive manufacturing and near-net-shape manufacturing. The company developed proprietary titanium processing technologies including hydrogen assisted metallothermic reduction (HAMR), hydrogen sintering and phase transformation (HSPT), and granulation-sintering-deoxygenation (GSD). Its products and services targeted industrial end markets such as aerospace, medical devices, and other specialty manufacturing applications rather than therapeutics or healthcare delivery. Blacksand also provided R&D services, pilot-scale powder production, powder characterization, and additive manufacturing test-part support. The company was founded in 2013 in Utah and its assets and intellectual property were acquired by IperionX, with the acquisition completed in November 2024 following an earlier option agreement announced in October 2021.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Blacksand Technology.